Clinical trial
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium…
NCT00468728 · Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00468728 |
|---|---|
| Title | PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) |
| Official title | A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD) |
| Lead sponsor | Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Clostridium Infections, Diarrhea |
| Intervention type | Drug |
| Interventions | PAR-101/OPT-80, Vancomycin |
| Enrollment | 535 |
| Start date | Oct 4, 2006 |
| Primary completion | Dec 11, 2009 |
| Completion | Dec 11, 2009 |
| First posted | May 3, 2007 |
| Last update posted | Apr 21, 2017 |
| Countries | Belgium, Canada, France, Germany, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: